Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy

Elena Marrosu,1 Pierpaolo Ala,1 Francesco Muntoni,1 and Haiyan Zhou1

1Dubowitz Neuromuscular Centre, Molecular Neurosciences Section, Developmental Neurosciences Programme, University College London, Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK

INTRODUCTION

Collagen-VI-related congenital muscular dystrophies (COL6-CMD) are the second most common diagnosis in congenital muscular dystrophies according to a recent retrospective review performed by our center on genetic studies in childhood neuromuscular diseases in the UK population.1 The collagen-VI-related myopathies, ranging from severe Ullrich congenital muscular dystrophy (UCMD) to mild Bethlem myopathy (BM) and intermediate clinical phenotypes, are caused by mutations in one of the genes that encode the three major α chains of collagen type VI: COL6A1 (MIM*120220), COL6A2 (MIM*120240), and COL6A3 (MIM*120250).2,3 The severe UCMD is an early-onset CMD variant that presents with slowly progressive muscle weakness, progressive joint contractures, and respiratory failure and the frequent development of severe scoliosis.4 Currently, there is no cure for COL6-CMD.

Collagen VI is one of the microfibrillar components of the extracellular matrix (ECM) expressed in a wide variety of tissues and shows a particular association with basement membranes by interacting with cells indirectly via components of the basal lamina.5 Collagen VI undergoes an extensive assembly process inside the cell before being secreted into the ECM. The assembly begins with the formation of the basic monomer, which is composed of one of each of the three α chain subunits encoded by the three collagen 6 genes. Within the cell, these monomers associate to form dimers, which then pair up into tetramers. These tetramers are then secreted into the ECM, where they assemble in an end-to-end fashion to give rise to the final microfibrillar network.6 Mutations in any of the three collagen 6 genes disrupt the correct formation of tetramers and they consequently fail to be secreted into the ECM to form collagen VI microfibrillar structures (Figure 1).3 The role of collagen VI in muscle is not completely understood. A role in mitochondrial survival had been previously reported.7 A more recent study in organizing the satellite cell niche, which regulates muscle regeneration, was also demonstrated.8

Bethlem myopathy is almost exclusively caused by dominant COL6A1, COL6A2, or COL6A3 mutations, whereas UCMD occurs as a result of both recessive and dominant mutations. In populations with a low degree of consanguinity, de novo autosomal-dominant mutations are the most common underlying mechanism of UCMD.3,8 There are two common types of dominant mutations in COL6-CMD: one is represented by in-frame deletions or splice site mutations causing in-frame exon skipping and another is represented
by missense mutations. These types of mutations act in a dominant-negative fashion due to the failure in incorporating the mutated α chain subunits into collagen VI monomers. Interestingly, complete deletion of one copy of the three COL6A genes is not associated with any clinical phenotypes, as indicated by the parents of children affected by the recessive variant, who may carry nonsense mutations or a large genomic deletion but remain completely asymptomatic. This suggests that suppression of one allele of the COL6A gene is not associated with a clinical phenotype and therefore may be used as a therapeutic strategy. Specifically, it has been hypothesized that silencing the mutated allele in one of the COL6A genes by allele-specific antisense oligonucleotides (AONs) may correct the abnormal collagen VI expression in CMD caused by dominant mutations. The fact that dominant-negative mutations account for 50%–75% of UCMD cases and nearly 100% of BM cases makes an allele-specific silencing approach an interesting therapeutic strategy for a large proportion of COL6-CMD patients.

Encouraging data have been reported recently from a study using AON to target an SNP and induce out-of-frame exon skipping in the COL6A2 gene to deplete the mutated transcript via RNA nonsense-mediated decay. The preferential skipping of the target exon via SNP recognition recovered the production of functional collagen VI in cultured fibroblasts from a patient with UCMD. This approach was further supported by two additional studies using a small interfering RNA (siRNA) approach to selectively silence the mutant allele, which carries the heterozygous exon 16 deletion in the COL6A3 gene and the missense c.850G > A (p.G284R) mutation in the COL6A1 gene. These studies provide the proof of principle for allele-selective suppression by different RNA-based approaches as a therapeutic strategy in COL6-CMD.

In this study, we describe the investigation of gapmer AONs for allele-specific silencing (Figure 1). Gapmer AONs were designed to selectively bind to the mutant allele to induce target RNA degradation by activating RNase H, an endonuclease that cleaves the RNA strand of a DNA-RNA duplex. A skin fibroblast cell line from a UCMD patient carrying a de novo 18-nt genomic deletion in exon 15 of the COL6A3 gene was selected as an in vitro model. A series of gapmer AONs were designed with various combinations in length by targeting the premature mRNA (pre-mRNA) and mRNA, respectively. Our study shows that gapmer AONs can selectively suppress the expression of the mutant transcripts while not interfering with the wild-type transcripts. Functionally, AON treatment significantly reduces the intracellular retention of the collagen VI complex and increases the secretion of a functional protein in the ECM. This is a
major step forward in establishing the allele-specific silencing by AON as a therapeutic strategy for the treatment of dominant COL6-CMD.

RESULTS

Gapmer AONs Designed to Bind the Deletion Site of COL6A3 and Target Either Pre-mRNA or mRNA Products

Gapmer AONs were designed to stimulate RNA degradation through the recruitment of RNase H. In humans, the specific enzyme recruited by the AON-RNA duplex is RNase H1. It has been reported that RNase H active AONs exert their action predominantly in the nucleus, where they interact with the pre-mRNA, whereas in other reports, mRNA in the cytoplasm is the predominant target of RNase H active AONs. To understand if the gapmer AONs preferentially target the pre-mRNA or mRNA of the COL6A3 gene, we selected a fibroblast cell line carrying a specific genomic deletion in exon 15 of COL6A3 as the cellular model. This 6-aa in-frame deletion is near the amino terminus of the triple helical domain and plays a strong dominant-negative effect.

Deletion of 18 nt near the 3' end of exon 15 results in different sequences of pre-mRNA and mRNA. Therefore, unique gapmer AONs can be designed to anneal to pre-mRNA or mRNA, respectively (Figure 2). We followed the classic design of gapmer AON: the RNase H activating phosphorothioate DNA domain (DNA gap) is flanked by short RNA sequences at each end with 2'-OMe backbone at both ends (wings) to protect the AONs from degradation by nucleases.

Two groups of gapmer AONs were designed to target either the pre-mRNA or mRNA. Three different lengths of AONs, 16-mer, 18-mer, and 22-mer, were designed; these were associated with a different length of the DNA gap, between 6 nt and 12 nt (Table 1).

Gapmer AONs Silence the Mutant mRNA Transcripts Preferentially at the mRNA Level

The difference between the wild-type transcript and the mutant transcript in this cell line is that the wild-type transcript is 18 bp longer than the mutant one when the same primers are used to amplify the PCR products flanking the mutation region. This, therefore, provides us with a practical tool to distinguish the two transcripts by gel electrophoresis. To test the efficiency of AONs on suppressing the mutant allele, we performed semiquantitative reverse transcript one-step PCR. RNA samples were isolated from the patient’s fibroblast cell line treated with different gapmer AONs at 100 nM for 24 hr. The percentage of PCR band intensity of the mutant COL6A3 transcripts fragment (lower PCR band) to total COL6A3 transcripts fragment (wild-type transcript/top PCR band + mutant transcript/lower PCR band) was used to measure the efficiency of mutant allele silencing.

In untreated or scrambled AON-treated fibroblasts, there was approximately 60%–70% expression of mutant to total COL6A3 transcripts. The mutant transcripts were dramatically reduced after AON treatment. Gapmer AONs suppressed the expression of mutant transcripts at both mRNA (Figure 3A) and pre-mRNA levels (Figure 3B). AONs targeting mRNA achieved more significant suppression on the mutant transcripts compared to the scrambled control (Figure 3B). However, in the mRNA-targeting group, the mutant transcripts were 50%–100% suppressed compared to control. The most striking suppression was detected in cells treated with the 22-mer gapmer AONs. Among them, the AONs with an 8-nt DNA gap (AON-1) and the 18-mer AON with an 8-nt DNA gap (AON-4), which showed approximately 80%–85% silencing of the mutant transcripts. The short 16-mer AONs with a 6- and 8-nt DNA gap (AON-6 and AON-5) also showed mutant-allele silencing, although to a lesser extent, and achieved approximately 50%–60% suppression. In addition to the semiquantitative one-step PCR, we performed Sanger
To understand the range of effective concentrations of the lead AONs, we lowered the AON concentration to 10 nM and measured the effect on mutant-allele suppression. At 10 nM, we observed a reduction of approximately 80% on the mutant transcripts (Figure 4A). By using ANOVA, we compared the effect of AON-3 on COL6A3 transcripts in fibroblasts from healthy controls and UCMD patients. Control fibroblasts were treated with AON-3 at 20, 50, and 100 nM for 24 hr. Quantitative reverse transcript real-time PCR was performed to measure the abundance of the wild-type COL6A3 transcripts (Figure 4D), normalized to endogenous 18S transcripts. At 100 nM, COL6A3 wild-type transcripts were reduced by approximately 50% (p < 0.05). A slight reduction (~25%) of the wild-type transcripts was also detected in 50 nM AON-3 treated cells, although this was not statistically significant. No transcript reduction occurred in cells treated at 20 nM. We therefore chose 20 nM as the concentration for the subsequent protein studies.

**Gapmer AONs Decreased Intracellular Collagen VI Retention and Increased Collagen VI Deposition in the ECM in UCMD Fibroblasts**

Significant accumulation of intracellular collagen VI is a typical feature in cultures of UCMD fibroblasts. The UCMD fibroblasts used in this study displayed strong intracellular collagen VI retention, detected when collagen VI protein was stained on permeabilized cells treated with 0.1% Triton in blocking buffer (Figure 5). Patient fibroblasts were treated with 20 nM AON-2 and AON-3 for 24 hr in transfection medium and then replaced with growth medium with 50 µg/mL ascorbic acid for another 24 hr before being processed for immunostaining. The retention of intracellular collagen VI was markedly reduced and accompanied by increased collagen VI protein deposition in the ECM (Figure 5).

In unpermeabilized cells, where immunofluorescence staining only detects collagen VI in the ECM, collagen VI fibrils were dramatically reduced in patient fibroblasts and replaced by a discontinuous and speckled staining pattern (Figure 6). After a single AON-3 treatment at 20 nM, the pattern of collagen deposition changed to linear fibrils, similar to the pattern in healthy control fibroblasts (Figure 6).

Fibronectin is another major component of the ECM and associates with collagen VI in cultured fibroblasts, although the two microfibrillar systems do not completely co-localize. To examine the effect of AON treatment on the organization of collagen VI and fibronectin in UCMD fibroblasts, we performed double staining of collagen VI and fibronectin in the unpermeabilized cells (Figure 7A). Studies in Col6a null mice and CMD patient fibroblast cultures showed that fibronectin levels and expression were similar to controls and indicates that the synthesis and secretion of fibronectin is not dependent on collagen VI synthesis or its secretion in the culture medium. We therefore performed semiquantitative fluorescence imaging analysis of ECM collagen VI abundance and used fibronectin as a control for immunostaining.
ECM protein marker. Images were analyzed and quantified using ImageJ software. The analysis of the area of collagen-VI-positive fibrils relative to that of fibronectin-positive fibrils was compared between scrambled and AON-3-treated patient fibroblasts and healthy control fibroblasts. There was a strong reduction in ECM collagen VI abundance in the scrambled AON-treated patient’s fibroblast compared to the healthy control (p < 0.0001), and was significantly increased after AON-3 treatment (p < 0.01), although the expression was still below the level of the healthy control (p < 0.05) (Figure 7B).

To quantitatively determine the change of ECM collagen VI, we performed flow cytometry of collagen VI mRNA in cultured fibroblasts. The standard operating procedure of the collagen VI flow cytometry assay used in the diagnostic services in our laboratory is a 5-day procedure, starting from fibroblast seeding to final cell harvest for detection. Considering the longer procedure time (5 days) than immunohistochemistry (2 days), we therefore performed two consecutive transfections in fibroblast cultures. Patient fibroblasts received two 20 nM AON-2, AON-3, or scrambled AON (AON-Scr) treatments at 48-hr intervals and 50 μg/mL L-ascorbic acid for 24 hr on the last day before being processed for the flow cytometry assay. The mean fluorescence intensity (MFI) in the scrambled AON-treated fibroblast (1,641 ± 35.69; n = 3) was dramatically reduced compared to the healthy control (4,117 ± 222.8; n = 3; p < 0.0001). This equated to 40% of healthy control levels. The MFI in patient fibroblasts was significantly improved after AON-2 (2,653 ± 11.17; n = 3; p < 0.001) and AON-3 (2,570 ± 155.7; n = 3; p < 0.001) treatment to approximately 60% of the healthy control levels (Figure 8).

DISCUSSION
In this study, we describe for the first time the development of an allele-specific silencing approach using gapmer AONs to diminish the dominant-negative effect in a UCMD fibroblast cell line carrying a dominant mutation in the COL6A3 gene.

Gapmer is a chimeric AON that contains a central sequence of phosphorothioate DNA nucleotides ("DNA gap") flanked by sequences of modified RNA residues at each end to protect the DNA gap from nuclease degradation, whereas the central DNA gap region allows...
Figure 4. AON-3 Suppressed the Mutant Transcripts in a Dose-Dependent Manner

(A) One-step reverse transcript PCR of mRNA isolated from patient fibroblasts treated with 13 AONs at 10 nM. Measurement was performed in three individual experiments (n = 3 per concentration). *AON-2 and AON-3 exhibited the most efficient suppression, over 80%, on the mutant transcripts. (B) Comparison of the efficiency of AON-3 (22-mer), AON-4 (18-mer), and AON-5 (16-mer), all with the same 8-nt DNA gap, in suppressing the mutant transcripts at concentrations of 10 nM and 100 nM, respectively. There was a significant difference between AONs with different lengths (*p < 0.05; **p < 0.01; ***p < 0.001; n = 3 per group). (C) Fibroblasts were treated with AON-3 at a range of concentrations of between 1 nM and 20 nM. The IC_{50} was identified at 5–10 nM. There was an approximately 90% reduction of the mutant transcripts in cells treated at 20 nM (n = 4 per concentration). (D) Effects of AON-3 on wild-type transcripts (n = 3 per concentration). At 100 nM, approximately 50% of wild-type COL6A3 transcripts were affected (*p < 0.05). No transcript reduction was detected at 20 nM. Data are presented as mean ± SEM.
In this study, we designed two groups of gapmer AONs that targeted mRNA and pre-mRNA sequences, respectively. Our study showed that although both groups presented efficiency in allele-specific silencing, the AONs targeting mRNA levels are superior to those targeting pre-mRNA levels (Figure 3). In this case, it is possible that both nucleus and cytoplasmic RNase H mechanisms are involved in this process. The differential efficiencies between AONs targeting exon and intron sequences have also been reported previously in other genes. Possible reasons why AONs targeting mRNA sequences work better than pre-mRNA sequences in the COL6A3 gene may include (1) the difference in the secondary structures of the two sequences; (2) different uptake efficiency of AONs in different cellular compartments; and (3) cellular localization of target transcripts. The secondary structure of the target mRNA or pre-mRNA is an important determinant of activity for all RNA-related therapies, including siRNA and AONs for gene silencing and splicing modulation. It is assumed that the predicted secondary structure of the mutant allele at the pre-mRNA level containing intron sequences is different from the structure of mature mRNA in this case. The cellular uptake of AON is predominantly mediated by endocytosis. AONs then continuously shuttle between cytoplasm and the nucleus through yet an unidentified cellular pathway with molecules that undergo nucleo-cytoplasmic transport. Understanding of the pathways that result in efficient AON trafficking to different intracellular active compartments, and especially between cytoplasm and nucleus, will help to figure out the difference observed above between the two AON target groups. It is thought that mature protein-coding mRNAs predominantly reside in the cytoplasm for subsequent protein synthesis, whereas pre-mRNA exclusively resides in the nucleus. It is therefore possible that the abundant COL6A3 transcripts in the cytoplasm of the cell line in our study may influence the gapmer AON activities.

To elicit mRNA degradation by RNase H, a gap of at least 5 consecutive phosphorothioate DNA nt, with 7–10 being optimal, is usually incorporated into the design of gapmer AON. In this study, we compared a number of different lengths of the gapmer AON sequences (16-, 18-, and 22-mer), and the central DNA gap (6, 8, 10, and 12 nt). Our findings showed that the best antisense activity was found with 22-mer gapmers and a DNA gap size of between 8 and 10 nt (Figures 3 and 4). Length of AONs is also an important parameter in determining the antisense activities in different applications. Gapmer AONs are typically composed of 16–22 nt for general gene silencing. Usually, the longer the sequence, the stronger the binding affinity. However, in the case of allele-specific gene silencing, a long AON sequence may reduce its specificity in discriminating the mutant and wild-type alleles. Therefore, calibrating the length of AONs and the size of the DNA gap is required in the design of allele-specific silencing gapmer AONs.

The effective concentration (IC₅₀) of the lead gapmer AON determined in this study was as low as 5–10 nM (Figure 4C). An undesirable and significant off-target effect on the wild-type transcripts was detected at the higher concentration of 100 nM. Although it is 10-fold higher than the IC₅₀ the possibility of adverse events related to the targeting of the wild-type sequence by the gapmer AON needs to be taken into consideration when evaluating future in vivo studies. Newer generations of oligonucleotide chemical modifications may be applied to overcome this limitation of gapmer AON in the 2′-OMe backbone.

Further chemical modifications of the sugar at the 2′ position, such as 2′-O-Me, 2′-O-methoxy-ethyl (2′-MOE), and locked nucleic acids...
(LNAs), improve the RNA-binding affinity, increase resistance to the endonuclease, decrease toxicity, and prolong tissue half-life and preserve RNase H activation to the RNA:AON duplex. LNA gapmer AONs with two or three LNA moieties placed at the 3' and 5' ends have been widely used in gene silencing. However, the striking acute hepatotoxicity induced by some LNA gapmer AONs in mice in preclinical studies have limited the clinical development of this chemical modification. In contrast, 2'-MOE gapmer AONs have a more favorable safety profile, as suggested by a number of clinical studies. Moreover, systemically administered MOE gapmer AONs, when targeting transcripts with prolonged nuclear residence, can enter skeletal muscle fibers and cause rapid target gene knockdown via RNase H1 in the transgenic mouse model of myotonic dystrophy. Gapmer AONs with another sugar modification, such as the 2'-deoxy-2'-fluoro-β-D-arabinonucleic acid (2F-ANA), have also improved RNase H activity and reduced cell toxicity. We only measured the cellular activity of gapmer AON with the 2'-OMe modification in this study. Investigations of more chemical modifications, such as MOE and 2F-ANA, may provide more efficient candidates for the allele-specific silencing approach in COL6-CMD.

Because interstitial fibroblasts are the main source of collagen 6 synthesis in skeletal muscle, the uptake and efficiency of gapmer AONs in skeletal-muscle-originated interstitial fibroblasts is yet to be elucidated. Although modified AONs such as MOE, LNA, 2F-ANA, and other emerging ones may improve the biodistribution, advanced technology, such as cell-penetrating peptide-mediated oligonucleotide therapy, may also provide further benefit.

Allele-specific knockdown using siRNA has been reported to efficiently and selectively silence the mutant mRNA transcripts in UCMD with dominant mutations in COL6 genes, such as the heterozygous exon 16 deletion in the COL6A3 gene, and the missense c.850G > A (p.G284R) mutation in the COL6A1 gene. Treatment with lead siRNAs reduced intracellular collagen VI retention and increased the quantity and quality of collagen VI microfibrils assembled in the ECM. Although siRNA is potent and effective in gene silencing in in vitro cell-based assays, hurdles such as the poor in vivo stability of the unmodified nucleotides, passive delivery and ineffective uptake to target cells, potential off-target effects, and immune stimulation have hampered its translation from the bench to further clinical application. Approaches, including chemical modifications of the RNA bases and packaging into advanced in vivo delivery cargos and an alternative form of short hairpin RNAs (shRNAs) with viral vectors, may be applied to improve the stability and uptake of siRNA in vivo.

AON technology offers great potential for conditions that cannot be impacted by traditional drugs. This technology has been applied as experimental therapies in a number of neuromuscular disorders by targeting different modulatory mechanisms in RNA processing and has shown tremendous potential in treating these otherwise untreatable diseases. The two very recent accelerated approvals by the Food and Drug Administration (FDA) of Eteplirsen, a phosphorodiamidate morpholino AON that modulates splicing in the Dystrophin gene to treat patients with Duchenne muscular dystrophy, and Nusinersen, an MOE AON that modulates splicing in the SMN2 gene to treat patients with spinal muscular atrophy, are a huge step forward in facilitating AONs as therapeutic strategies in genetic diseases and will undoubtedly promote similar development in other neuromuscular diseases. Our group and others have provided strong and promising proof-of-concept studies on allele-specific silencing as a therapeutic strategy for COL6-CMD by investigating various RNA-related approaches. Future studies on the efficacy of gapmer AON-induced allele-specific silencing in vivo in animal models are required prior to its translation to clinical evaluation.

In conclusion, we have designed and critically evaluated gapmer AONs to elicit allele-specific silencing on dominant mutation in the COL6A3 gene in patient fibroblasts. Gapmer AONs targeting mRNA sequences, with a length of 22-mer and a DNA gap size of 8–10 nt gave the most efficient allele-specific silencing effect. The effective concentration can be as low as 5–10 nM, whereas a high concentration is associated with off-target effects. This design principle can be applied to target a broad range of mutations with dominant-negative effects in any COL6A1, COL6A2, and COL6A3 genes. This AON approach may benefit more than 50% of UCMD and nearly all Bethlem myopathy patients that are affected by dominant mutations in one of three COL6A genes. The next step will be to

Figure 6. Effect of AON-3 on Collagen VI Deposition in the ECM
Representative images of collagen VI α3 staining (in green) in unpermeabilized fibroblasts treated with scrambled AON (UCMD+AON-Scr), AON-3 (UCMD+AON-3), and healthy control fibroblasts. Higher magnification of the images is presented in the lower panel. Scale bar, 25 μm and 50 μm, respectively.
validate gapmer AONs in different chemical modifications and in vivo in the relevant mouse model and eventually translate to clinical studies.

MATERIALS AND METHODS

**COL6A3 Mutation and AON Design**

The mutation in the UCMD patient whose fibroblasts were used for this study is a heterozygous 18-nt genomic deletion in exon 15 of the COL6A3 gene (c.6135_6152del; p.Ile2046_Pro2051del). This de novo in-frame 6-aa deletion has been confirmed at both genomic DNA and mRNA levels (Table 1). The RNase H activating ps DNA domain (DNA gap) is flanked by short RNA sequences in the 2’-OMe backbone at the 5’ and 3’ end to protect the AONs from degradation by nucleases. Lengths ranging from 16 to 22 bases for the entire sequence and 6 to 12 bases for the DNA gap were designed and analyzed in the study.

**Cell Culture and Transfection**

A fibroblast cell line was established from a skin biopsy of the patient with written informed consent of parents. The Declaration of Helsinki protocols were followed. The study was approved by the Berkshire Research Ethics Committee (REC reference 05/MRE 12/32). Fibroblasts were supplied by the MRC Center for Neuromuscular Diseases Biobank London (REC reference number 06/Q0406/C and 5% CO2. Cells were seeded into six-well plates at a concentration of 2 × 10⁴ cells per well, which gives 90% confluence when transacted on the next day. For the immunofluorescence study, a 12-mm diameter glass coverslip pre-coated with collagen (BD Discovery) was placed in the culture dish before cell seeding. Lipofectamine 2000 (Life Technologies) was used as the transfection reagent to complex AONs in Opti-MEM (Life Technologies) according to the manufacturer’s instructions.

**Reverse-Transcription One-Step PCR and Gel Analysis**

For studies at the RNA level, fibroblasts were treated with gapmer AONs at final concentrations ranging from 1 to 100 nM in transfection medium. Cells were harvested 24 hr post-transfection for RNA extraction. Total RNA from the cultured cells was extracted with the RNeasy kit (QIAGEN). The concentration of total RNA was measured by the NanoDrop spectrophotometer (Thermo Scientific). The amount of 100 ng of total RNA was used in one-step reverse-transcription PCR (QIAGEN) to amplify the transcripts. The primers (forward: 5’-TGG GCA GAG GGG AGA C-3’ and reverse: 5’-TCT TCT CCA GGA ATA CCC TTT-3’) were used to amplify the wild-type allele (82 bp) and mutant allele (64 bp). A 240-bp PCR product was also amplified for Sanger sequencing, with forward primer: 5’-CCC TGA GGC TTA ACT TGC TG-3’ and reverse primer: 5’-AAA CCT TGA GTG CCG TTC AC-3’). The products were amplified semiquantitatively as follows: a reverse-transcription reaction at 50°C for 30 min and the initial PCR activation step at 95°C for 15 min. These were followed by three-step cycling as denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s, for a total of 26 cycles, and finished at 72°C for 10 min as the final extension. PCR samples were run on a 3% (for the 64- and 82-bp products) or 2% (for the 240-bp product for sequencing) agarose gel and visualized under the Gel Doc XR imaging system (Bio-Rad). The intensity of each PCR band was quantified using ImageJ software (https://imagej.nih.gov). Sanger sequencing service was provided by Source BioScience.

**Quantitative Reverse-Transcript Real-Time PCR**

500 ng of RNA was used for first-strand cDNA synthesis with a Superscript III reverse transcription kit (Life Technologies). Quantitative real-time PCR was performed using the Takyon Rox SYBR qPCR kit (Eurogentec). The primer set, forward 5’-CAT CGG CAT CGG-3’ (in exon 15) and reverse 5’-AAA CCT TGA GTG CCG TTC AC-3’ (in exon 17), was used for the amplification of a 117-bp product of the wild-type COL6A3 gene in healthy control...
PCR and analysis were performed with StepOne real-time PCR systems (Applied Biosystems) using the recommended program: activation at 95°C for 3 min, 40 cycles of denaturation at 95°C for 3 s, and annealing extension at 60°C for 30 s. Human 18S was used as the reference gene. Quantification was based on concurrent standard curves produced from serial dilutions of cDNA from the untreated healthy control fibroblasts. The cycle at which the amount of fluorescence was above the threshold (Ct) was detected. The ratios of wild-type COL6A3 to 18S of the treated samples were normalized, taking the ratio of the untreated sample as 1.0.

Immunofluorescence Staining
24 hr after AON transfection, the culture medium was changed to growth medium containing 50 µg/mL ascorbic acid for another 24 hr. Cells on coverslips were then fixed with 4% paraformaldehyde for 10 min at room temperature and rinsed in PBS. After 1-hr blocking in 5% goat serum in PBS, coverslips were incubated for 1 hr at room temperature with the following primary antibodies: rabbit anti-collagen VI alpha3 chain-specific antibody (HPA010080; dilution 1:50, Sigma-Aldrich) and mouse anti-fibronectin antibody (F0791; dilution 1:100, Sigma-Aldrich). For intracellular collagen VI staining, 0.1% Triton was added in the blocking buffer for cell permeabilization. Coverslips were washed three times in PBS and then incubated with secondary antibodies (goat anti-mouse Alexa-594 and goat anti-rabbit Alexa 488; 1:500 dilution; Life Technologies) in PBS for 1 hr at room temperature. Coverslips were washed three times and nuclei were stained with Hoechst 33258 (Promega) for 5 min. Coverslips were mounted with Fluoromount (Southern-Biotech) and viewed under the Leica DMR fluorescence microscope. Images were captured digitally using Metamorph software (Universal Imaging), with fixed setting on exposure for all the slides. The semiquantification of ECM collagen VI expression in immunofluorescence staining was analyzed by ImageJ software, normalized to fibronectin ECM expression captured in the same image.

Flow Cytometry Analysis
1.0 × 10^6 fibroblasts were seeded in 75 cm² tissue culture flasks (BD) in growth medium to achieve 90% confluence on the next day. Cells were transfected with AONs at 20 nM. 24 hr after this, the medium was replaced with growth medium for another 24 hr. This was then
followed by the second 24-hr AON transfection, and medium was changed to growth medium for a further 24 hr. 50 μg/mL ascorbic acid was added for the final 24-hr incubation. Cells were detached using a non-enzymatic cell dissociation solution (Sigma), washed twice with PBS (Mg²⁺ and Ca²⁺ free, Life Technologies), and centrifuged for 5 min at 500 × g. Cells were fixed by incubating with 2% paraformaldehyde in PBS for 15 min on ice. Following fixation, cells were washed three times with PBS supplemented with 0.1% FBS and centrifuged at 1,850 × g for 4 min. Cell pellets were re-suspended and incubated with the polyclonal rabbit anti-collagen VI α3 chain-specific antibody (HPA010080; dilution 1:20, Sigma) diluted in PBS/0.1% FBS for 30 min on ice, washed twice in PBS/0.1% FBS, and centrifuged at 1,850 × g for 4 min. For a negative control in each group, cells were incubated with an equivalent amount of 0.1% FBS/PBS without the primary antibody. Cells were then incubated with donkey anti-rabbit immunoglobulin G (IgG) conjugated to Alexa Fluor 647, (A-31573; dilution 1:100; Life Technologies) diluted in PBS/0.1% FBS for 20 min on ice, washed twice in PBS/0.1% FBS, and centrifuged at 1,850 × g for 4 min. Cell pellets were re-suspended in PBS and transferred to FACS tubes (BD Biosciences). Cells were immediately analyzed using the CyAn ADP Flow Cytometer equipped with a 488-nm blue laser and a 635-nm red diode (Beckman Coulter). A total of 10,000 cells were acquired and subsequently analyzed using FlowJo software version 7.6.5 (Tree Star). The negative control was used to set up the collagen VI gate and remove the level of background fluorescence. The amount of collagen VI was assessed by the MFI of ECM collagen VI α3 expression.

Statistical Analysis
GraphPad Prism 5.0 software was used for statistical analysis and graph design. Data were presented as mean ± SEM. One-way ANOVA and post Bonferroni test were used to determine statistical significance when comparing more than two groups. Student’s t test was used for statistical analysis of two groups of data.

AUTHOR CONTRIBUTIONS
E.M., P.A., and H.Z. conducted the experiments; H.Z. and F.M. designed the experiments and wrote the paper.

CONFLICTS OF INTEREST
The authors declare no conflicts of interest.

ACKNOWLEDGMENTS
This work was supported by the Muscular Dystrophy UK (RA2/3044 to F.M. and H.Z.) and the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London (grant code 513408 to F.M. and H.Z.). We would like to thank Professor Jenny Morgan for her critical reading and comments on the manuscript. The MRC Centre for Neuromuscular Diseases Biobank is greatly appreciated for providing patients’ fibroblast cell lines. The Muscular Dystrophy UK support to the Dubowitz Neuromuscular Centre is also gratefully acknowledged.

REFERENCES
1. Clement, E.M., Feng, L., Mein, R., Sewry, C.A., Robb, S.A., Manzur, A.Y., Mercieri, E., Godfrey, C., Cullup, T., Abbs, S., et al. (2012). Relative frequency of congenital muscular dystrophy subtypes: analysis of the UK diagnostic service 2001-2008. Neuromuscul. Disord. 22, 522–527.
2. Foley, A.R., Quijano-Roy, S., Collins, J., Straub, V., McCallum, M., Deconinck, N., Mercieri, E., Pane, M., D’Amico, A., Bertini, E., et al. (2013). Natural history of pulmonary function in collagen VI-related myopathies. Brain 136, 3625–3633.
3. Bönnemann, C.G. (2011). The collagen VI-related myopathies: muscle meets its matrix. Nat. Rev. Neurol. 7, 379–390.
4. Nadeau, A., Kinali, M., Main, M., Jimenez-Mallebrera, C., Alievius, A., Clement, E., North, B., Manzur, A.Y., Robb, S.A., Mercieri, E., et al. (2009). Natural history of Ullrich congenital muscular dystrophy. Neurology 73, 25–31.
5. Engvall, E., Hesse, H., and Klier, G. (1986). Molecular assembly, secretion, and matrix deposition of type VI collagen. J. Cell Biol. 102, 703–710.
6. Furthmayr, H., Wiedemann, H., Timpl, R., Odermatt, E., and Engel, J. (1983). Electron-microscopical approach to a structural model of intima collagen. Biochem. J. 211, 303–311.
7. Bernardi, P., and Bonaldo, P. (2013). Mitochondrial dysfunction and defective autophagy in the pathogenesis of collagen VI muscular dystrophies. Cold Spring Harb. Perspect. Biol. 5, a011387.
8. Urcuolo, A., Quarta, M., Morbidoni, V., Gattazzo, F., Molon, S., Grumati, P., Montemurro, F., Tedesco, F.S., Blazew, B., Costu, G., et al. (2013). Collagen VI regulates satellite cell self-renewal and muscle regeneration. Nat. Commun. 4, 1964.
9. Baker, N.L., Mörgelin, M., Peat, R., Goemens, N., North, K.N., Bateman, J.F., and Lamandé, S.R. (2005). Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Hum. Mol. Genet. 14, 279–293.
10. Foley, A.R., Hu, Y., Zou, Y., Yang, M., Medne, L., Leach, M., Conlin, L.K., Spinner, N., Shaikh, T.H., Falk, M., et al. (2011). Large genomic deletions: a novel cause of Ullrich congenital muscular dystrophy. Ann. Neurol. 69, 206–211.
11. Allamand, V., Briéas, L., Richard, P., Stojiljkovic, T., Quijano-Roy, S., and Bonne, G. (2011). ColVI myopathies: where do we stand, where do we go? Skelet. Muscle 1, 30.
12. Briéas, L., Richard, P., Quijano-Roy, S., Gartioux, C., Ledeuil, C., Lacomme, B., Makri, S., Ferreiro, A., Maugener, S., Topaloglu, H., et al. (2010). Early onset collagen VI myopathies: genetic and clinical correlations. Ann. Neurol. 68, 511–520.
13. Hicks, D., Lampe, A.K., Barresi, R., Charlton, R., Fiallo, E., and Bönnemann, C.G., Hudson, J., Sutton, R., Lochmüller, H., Straub, V., et al. (2008). A refined diagnostic algorithm for Bethlem myopathy. Neurology 70, 1192–1199.
14. Gualandi, F., Manzati, E., Sabatelli, P., Passarelli, C., Bovolenta, M., Pellegrini, C., Perrone, D., Squarzoni, S., Pegoraro, E., Bonaldo, P., et al. (2012). Antisense-induced messenger deletion corrects a COL6A2 dominant mutation in Ullrich muscular dystrophy. Mol. Ther. 20, 1313–1318.
15. Bolyde, V., Zou, Y., Ko, D., and Bönnemann, C.G. (2014). siRNA-mediated allele-specific silencing of a COL6A3 mutation in a cellular model of dominant Ullrich muscular dystrophy. Mol. Ther. Nucleic Acids 3, e147.
16. Noguchi, S., Ogawa, M., Kawahara, G., Malicdan, M.C., and Nishino, I. (2014). Allele-specific gene silencing of mutant mRNA restores cellular function in Ullrich congenital muscular dystrophy fibroblasts. Mol. Ther. Nucleic Acids 3, e171.
17. Bennett, C.F., and Swayne, E.E. (2010). RNA targeting therapeutics: molecular mechanisms of antisense eligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259–293.
18. Deleavey, G.F., and Damha, M.J. (2012). Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol. 19, 937–954.
19. Wu, H., Lima, W.F., Zhang, H., Fan, A., Sun, H., and Crooke, S.T. (2004). Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279, 17181–17189.
20. Vickers, T.A., Koo, S., Bennett, C.F., Crooke, S.T., Dean, N.M., and Baker, B.C. (2003). Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278, 7108–7118.
21. Lampe, A.K., Zou, Y., Sudano, D., O’Brien, K.K., Hicks, D., Laval, S.H., Charlton, R., Jimenez-Mallebrera, C., Zang, R.Z., Finkel, R.S., et al. (2008). Exon skipping
mutations in collagen VI are common and are predictive for severity and inheritance. Hum. Mutat. 29, 809–822.

22. Agrawal, S., Mayrand, S.H., Zamecnik, P.C., and Pederson, T. (1990). Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 87, 1401–1405.

23. Jimenez-Mallebrera, C., Maio1i, M.A., Kim, J., Brown, S.C., Feng, L., Lampe, A.K., Bushby, K., Hicks, D., Flanagan, K.M., Bonnemann, C., et al. (2006). A comparative analysis of collagen VI production in muscle, skin and fibroblasts from 14 Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations. Neuromusc. Disord. 16, 571–582.

24. Sabatelli, P., Bonaldo, P., Lattanzi, G., Braghetta, P., Bergamin, N., Capanni, C., Mattioli, E., Columbaro, M., Ognibene, A., Pepe, G., et al. (2001). Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biol. 20, 475–486.

25. Kim, J., Jimenez-Mallebrera, C., Foley, A.R., Fernandez-Fuente, M., Brown, S.C., Torelli, S., Feng, L., Sewry, C.A., and Muntoni, F. (2012). Flow cytometry analysis: a quantitative method for collagen VI deficiency screening. Neuromusc. Disord. 22, 139–148.

26. Monia, B.P., Lesnik, E.A., Gonzalez, C., Lima, W.F., McGee, D., Guinosso, C.J., Kawasaki, A.M., Columbaro, M., Ognibene, A., Pepe, G., et al. (2001). Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biol. 20, 475–486.

27. Yu, R.Z., Grundy, J.S., and Geary, R.S. (2013). Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin. Drug Metab. Toxicol. 9, 169–182.

28. Evers, M.M., Toonen, L.J., and van Roon-Mom, W.M. (2015). Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv. Drug Deliv. Rev. 87, 90–103.

29. Kole, R., Krainer, A.R., and Altman, S. (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11, 125–140.

30. Lundin, K.E., Gissberg, O., and Smith, C.J. (2015). Oligonucleotide therapeutics: the past and the present. Hum. Gene Ther. 26, 475–485.

31. ten Asbroek, A.L., van Groenigen, M., Nooij, M., and Baas, F. (2002). The involvement of human ribonucleases H1 and H2 in the variation of response of cells to antisense phosphorothioate oligonucleotides. Eur. J. Biochem. 269, 583–592.

32. Cazenave, C., Frank, P., Toulouse, J.L., and Busing, W. (1994). Characterization and subcellular localization of ribonuclease H activities from Xenopus laevis oocytes. J. Biol. Chem. 269, 25185–25192.

33. Prasanth, K.V., Prasanth, S.G., Xuan, Z., Hearn, S., Freier, S.M., Bennett, C.F., Zhang, M.Q., and Spector, D.L. (2005). Regulating gene expression through RNA nuclear retention. Cell 123, 249–263.

34. Wheeler, T.M., Leger, A.J., Pandey, S.K., MacLeod, A.R., Nakamori, M., Cheng, S.H., Wentworth, B.M., Bennett, C.F., and Thornton, C.A. (2012). Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111–115.

35. Wilusz, J.E., Freier, S.M., and Spector, D.L. (2008). 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell 135, 919–932.

36. Castanotto, D., Lin, M., Kowalcik, C., Wang, L., Ren, X.Q., Soifer, H.S., Koch, T., Hansen, B.R., Oerum, H., Armstrong, B., et al. (2015). A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells. Nucleic Acids Res. 43, 9350–9361.

37. Lorenz, P., Misteli, T., Baker, B.F., Bennett, C.F., and Spector, D.L. (2000). Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 28, 582–592.

38. Frieden, M., Christensen, S.M., Mikkelsen, N.D., Rosenbom, C., Thure, C.A., Westergaard, M., Hansen, H.F., Òrum, H., and Koch, T. (2003). Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res. 31, 6365–6372.

39. Zhou, H., Janghpa, N., Mitoprant, C., Dickinson, R.L., Anthony, K., Price, L., Eperon, I.C., Wilton, S.D., Morgan, J., and Muntoni, F. (2013). A novel morpholino-oligomer targeting ISS-N1 improves severe spinal muscular atrophy transgenic mice. Hum. Gene Ther. 24, 331–342.

40. Harding, P.L., Fall, A.M., Honeyman, K., Fletcher, S., and Wilton, S.D. (2007). The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol. Ther. 15, 157–166.

41. Burel, S.A., Hart, C.E., Cauntay, P., Hsiao, J., Machemer, T., Katz, M., Watt, A., Bui, H.H., Younis, H., Sabriapour, M., et al. (2016). Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res. 44, 2093–2109.

42. Geary, R.S., Norris, D., Yu, R., and Bennett, C.F. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51.

43. Kalota, A., Karabon, L., Swider, C.R., Viazovkina, E., Elzabhig, M., Dham, M.J., and Gewirtz, A.M. (2006). 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing. Nucleic Acids Res. 34, 451–461.

44. Zou, Y., Zhang, R.Z., Sabatelli, P., Chen, M.L., and Bonnemann, C.G. (2008). Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J. Neuropathol. Exp. Neurol. 67, 144–154.

45. Sardone, V., Zhou, H., Muntoni, F., Ferlini, A., and Falzarano, M.S. (2017). Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules 22, 563.

46. Muntoni, F., and Wood, M.I. (2011). Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov. 10, 621–637.

47. Aartsma-Rus, A., and Krieg, A.M. (2017). FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen saga. Nucleic Acid Ther. 3, 355–358.

48. Geary, G., Garralda, M.E., Abbs, S., Wells, D.J., et al. (2011). Exon skipping and the present. Hum. Gene Ther. 22, 67–73.

49. Finkel, R.S., Chiriboga, C.A., Vajsar, J., Day, J.W., Montes, J., De Vivo, D.C., Finkel, R.S., Chiriboga, C.A., Vajsar, J., Day, J.W., Montes, J., De Vivo, D.C., and Krieger, A.M. (2017). FDA approves Eteplirsen for Duchenne muscular dystrophy. Nucleic Acid Ther. 3, 355–358.

50. Ottesen, E.W. (2017). ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl. Neurosci. 8, 1–6.